Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Current Liabilities (2017 - 2026)

Verrica Pharmaceuticals has reported Total Current Liabilities over the past 7 years, most recently at $16.2 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 44.83% year-over-year to $16.2 million; the TTM value through Mar 2026 reached $16.2 million, down 44.83%, while the annual FY2025 figure was $16.4 million, 43.34% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $16.2 million at Verrica Pharmaceuticals, down from $16.4 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $45.7 million in Q2 2022 and troughed at $2.6 million in Q1 2023.
  • A 5-year average of $20.2 million and a median of $19.4 million in 2024 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: plummeted 94.1% in 2023 and later surged 632.69% in 2024.
  • Year by year, Total Current Liabilities stood at $3.5 million in 2022, then soared by 392.17% to $17.0 million in 2023, then soared by 70.42% to $29.0 million in 2024, then plummeted by 43.34% to $16.4 million in 2025, then dropped by 1.33% to $16.2 million in 2026.
  • Business Quant data shows Total Current Liabilities for VRCA at $16.2 million in Q1 2026, $16.4 million in Q4 2025, and $28.9 million in Q3 2025.